Skip to main content

and
  1. No Access

    Article

    Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

    Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we unif...

    Diana Miao, Claire A. Margolis, Natalie I. Vokes, David Liu in Nature Genetics (2018)

  2. Article

    Open Access

    Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

    Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global...

    Johanna S. Song, Marianne Tawa, Nicole G. Chau, Thomas S. Kupper in BMC Cancer (2017)

  3. Article

    Open Access

    Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations

    Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understa...

    Yvonne Y Li, Grace T. Y. Chung, Vivian W. Y. Lui, Ka-Fai To in Nature Communications (2017)

  4. Article

    Open Access

    Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

    Preclinical and clinical studies suggest potential synergy between high dose per fraction focal radiation and immunotherapy. However, conventionally fractionated radiation regimens in combination with concurre...

    Vishwajith Sridharan, Danielle N Margalit, Stephanie A Lynch in British Journal of Cancer (2016)

  5. Article

    Open Access

    Immunologic profiling of adenoid cystic carcinoma (acc)

    Vishwajith Sridharan, **aoyun Liao, Nicole G Chau in Journal for ImmunoTherapy of Cancer (2015)

  6. Article

    Open Access

    Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

    Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of pa...

    Nicole G Chau, Ana Florescu, Kelvin K Chan, Lisa Wang, Eric X Chen in BMC Cancer (2011)

  7. Article

    Open Access

    The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

    We examine the potential prognostic and predictive roles of EGFR variant III mutation, EGFR gene copy number (GCN), human papillomavirus (HPV) infection, c-MET and p16 INK4A

    Nicole G Chau, Bayardo Perez-Ordonez, Katherine Zhang, Nhu-An Pham in Head & Neck Oncology (2011)